The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. / Dela, Flemming; Mallinson, Joanne; Greenhaff, Paul L.

Statin-Associated Muscle Symptoms. Contemporary Cardiology. red. / Paul D. Thompson; Beth A. Taylor. Springer, 2020. s. 113-120 (Contemporary Cardiology).

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Dela, F, Mallinson, J & Greenhaff, PL 2020, The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. i PD Thompson & BA Taylor (red), Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Contemporary Cardiology, s. 113-120. <https://link.springer.com/chapter/10.1007/978-3-030-33304-1_13>

APA

Dela, F., Mallinson, J., & Greenhaff, P. L. (2020). The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. I P. D. Thompson, & B. A. Taylor (red.), Statin-Associated Muscle Symptoms. Contemporary Cardiology (s. 113-120). Springer. Contemporary Cardiology https://link.springer.com/chapter/10.1007/978-3-030-33304-1_13

Vancouver

Dela F, Mallinson J, Greenhaff PL. The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. I Thompson PD, Taylor BA, red., Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer. 2020. s. 113-120. (Contemporary Cardiology).

Author

Dela, Flemming ; Mallinson, Joanne ; Greenhaff, Paul L. / The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms. Statin-Associated Muscle Symptoms. Contemporary Cardiology. red. / Paul D. Thompson ; Beth A. Taylor. Springer, 2020. s. 113-120 (Contemporary Cardiology).

Bibtex

@inbook{3b05bb4d5ed94588867a885ee84d6c5b,
title = "The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms",
abstract = "Animal models of overt statin myopathy reveal clear negative effects on muscle protein and carbohydrate metabolism, which appear to be linked to changes in Akt/FOXO signalling. Forcibly increasing muscle carbohydrate flux under these conditions by pharmacological means blocks statin myopathy. Human volunteer research has delivered less definitive mechanistic insight of the aetiology of statin-related metabolic dysregulation, with little evidence of profound changes in muscle protein and carbohydrate metabolism to date in statin myalgia. However, this may be at least partly explained by statin myalgic patients stopping or changing statin medication before overt muscle pathology has developed to anything like that resembling overt muscle myopathy. Several lines of evidence have associated statin therapy with increased risk of new-onset diabetes and dysregulation of glucose control, but the mechanisms underpinning these observations are currently unresolved.",
author = "Flemming Dela and Joanne Mallinson and Greenhaff, {Paul L.}",
year = "2020",
language = "English",
isbn = " 978-3-030-33303-4 ",
series = "Contemporary Cardiology",
publisher = "Springer",
pages = "113--120",
editor = "Thompson, {Paul D. } and Taylor, {Beth A. }",
booktitle = "Statin-Associated Muscle Symptoms. Contemporary Cardiology",
address = "Switzerland",

}

RIS

TY - CHAP

T1 - The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms

AU - Dela, Flemming

AU - Mallinson, Joanne

AU - Greenhaff, Paul L.

PY - 2020

Y1 - 2020

N2 - Animal models of overt statin myopathy reveal clear negative effects on muscle protein and carbohydrate metabolism, which appear to be linked to changes in Akt/FOXO signalling. Forcibly increasing muscle carbohydrate flux under these conditions by pharmacological means blocks statin myopathy. Human volunteer research has delivered less definitive mechanistic insight of the aetiology of statin-related metabolic dysregulation, with little evidence of profound changes in muscle protein and carbohydrate metabolism to date in statin myalgia. However, this may be at least partly explained by statin myalgic patients stopping or changing statin medication before overt muscle pathology has developed to anything like that resembling overt muscle myopathy. Several lines of evidence have associated statin therapy with increased risk of new-onset diabetes and dysregulation of glucose control, but the mechanisms underpinning these observations are currently unresolved.

AB - Animal models of overt statin myopathy reveal clear negative effects on muscle protein and carbohydrate metabolism, which appear to be linked to changes in Akt/FOXO signalling. Forcibly increasing muscle carbohydrate flux under these conditions by pharmacological means blocks statin myopathy. Human volunteer research has delivered less definitive mechanistic insight of the aetiology of statin-related metabolic dysregulation, with little evidence of profound changes in muscle protein and carbohydrate metabolism to date in statin myalgia. However, this may be at least partly explained by statin myalgic patients stopping or changing statin medication before overt muscle pathology has developed to anything like that resembling overt muscle myopathy. Several lines of evidence have associated statin therapy with increased risk of new-onset diabetes and dysregulation of glucose control, but the mechanisms underpinning these observations are currently unresolved.

M3 - Book chapter

SN - 978-3-030-33303-4

T3 - Contemporary Cardiology

SP - 113

EP - 120

BT - Statin-Associated Muscle Symptoms. Contemporary Cardiology

A2 - Thompson, Paul D.

A2 - Taylor, Beth A.

PB - Springer

ER -

ID: 238431412